Describe dicyclomimme on the basisi 9f pharmacology of veterinary science

I'll look up dicyclomine (likely what you mean by "dicyclomimme") in the veterinary pharmacology context right away.
Searching sources...
Reading File
Now I'll search the medical library and web in parallel for dicyclomine in veterinary pharmacology.
Finding Sources
Searching the Web

dicyclomine veterinary pharmacology uses mechanism antispasmodic animals

Now let me read the relevant textbook sections on dicyclomine for more depth.
Reading File
Finding Sources
I now have sufficient information to give a thorough answer. Here is a complete pharmacological description of dicyclomine with veterinary relevance:

Dicyclomine - Veterinary Pharmacology

1. Drug Identity

Dicyclomine (also spelled dicycloverine; brand names include Bentyl, Merbentyl) is a synthetic tertiary amine anticholinergic/antispasmodic agent. Its chemical name is 2-(diethylamino)ethyl bicyclohexyl-1-carboxylate hydrochloride (molecular formula C₁₉H₃₅NO₂·HCl; MW 345.95). It belongs to the same pharmacological class as atropine and hyoscine but with a distinctly different potency and receptor selectivity profile - classified as a Synthetic Tertiary Amine Antimuscarinic Compound alongside thiphenamil and cyclopentolate (Barash's Clinical Anesthesia, 9e).

2. Classification

PropertyDetail
Drug classAnticholinergic / Antispasmodic
Sub-classSynthetic tertiary amine antimuscarinic
Receptor targetMuscarinic acetylcholine receptors (M1, M2, M3)
Primary action siteGastrointestinal smooth muscle

3. Mechanism of Action (Dual Mechanism)

Dicyclomine acts through two distinct and complementary mechanisms - this is what makes it superior to purely anticholinergic drugs for GI spasm:

A. Anticholinergic (Antimuscarinic) Effect

  • Competitively blocks muscarinic acetylcholine (ACh) receptors on GI smooth muscle
  • Prevents ACh from binding, thereby reducing parasympathetic-driven smooth muscle contraction
  • Potency approximately 1/8th that of atropine at muscarinic receptors (tested in vitro in guinea pig ileum)
  • Much weaker than atropine on non-GI muscarinic sites:
    • ~1/500th the mydriatic potency of atropine (mice)
    • ~1/300th the antisialagogue potency of atropine (rabbits)
  • This selective GI targeting makes it more suitable in veterinary use with fewer systemic side effects

B. Direct Musculotropic (Papaverine-like) Effect

  • Directly relaxes GI smooth muscle independent of autonomic innervation
  • Antagonizes spasms induced by bradykinin and histamine - agonists that atropine cannot block
  • Equally potent against ACh-induced and barium chloride (BaCl₂)-induced intestinal spasm, while atropine is 200x more potent against ACh than BaCl₂
  • This musculotropic effect is especially valuable in animals with non-cholinergic GI spasms
This dual profile is pharmacologically significant: it covers both neurogenic and non-neurogenic spasm, broadening therapeutic utility.

4. Veterinary Uses

Though primarily a human GI drug, dicyclomine has documented animal pharmacology and veterinary applications:

Gastrointestinal Antispasmodic

  • Treatment of intestinal colic, spasm, and cramping in dogs, cats, and occasionally horses
  • Reduces excessive GI motility in irritable bowel syndrome (IBS) equivalents in small animals
  • Used in IBS-D (diarrhea-predominant) patterns - decreases GI spasms and motility
  • Adjunct in acute gastroenteritis with cramping

Urogenital Tract Spasm

  • Relieves smooth muscle spasm of the urinary tract (ureteral or bladder spasm)

Biliary Spasm

  • Occasional use in biliary colic involving smooth muscle of bile ducts

Pain Relief (Indirect)

  • Reduction of GI spasm alleviates associated pain - useful post-operatively or in colic episodes

5. Pharmacokinetics (Animal and Human Data)

ParameterDetails
Administration routesOral (tablet, suspension), Intramuscular injection
AbsorptionWell absorbed orally; peak plasma ~60-90 min after oral dose
DistributionWidely distributed; crosses blood-brain barrier poorly (tertiary amine)
MetabolismHepatic
EliminationBiliary and renal; half-life ~1.8 hrs (initial), ~9-10 hrs (secondary)
Protein bindingModerate
Unlike quaternary ammonium antimuscarinics (e.g., glycopyrrolate), dicyclomine's tertiary amine structure allows it to cross the BBB to a limited extent, contributing to its mild CNS effects.

6. Pharmacological Comparison with Atropine (Key Veterinary Drug)

FeatureDicyclomineAtropine
ReceptorMuscarinic (competitive block)Muscarinic (competitive block)
Musculotropic effectYes (direct on smooth muscle)No
Antisecretory potency~1/300thStrong
Mydriatic potency~1/500thStrong
Heart rate effectMild tachycardiaMarked tachycardia
GI spasm selectivityHighModerate
CNS penetrationLimitedYes
Dicyclomine is preferred over atropine when GI-selective action is needed without significant cardiovascular or ophthalmic side effects in veterinary patients.

7. Adverse Effects

In veterinary patients (extrapolated from animal studies and clinical use):
  • Anticholinergic effects: dry mouth (xerostomia), reduced salivation, constipation
  • CNS effects: mild sedation, restlessness (rare, due to limited BBB penetration)
  • Cardiovascular: mild tachycardia (much less than atropine)
  • Urinary retention: especially in male animals with prostatic disease
  • GI stasis: at high doses; risk of paralytic ileus
  • Hyperthermia: reduced sweating (relevant in active or working animals)
  • Blurred vision / cycloplegia: very rare at therapeutic doses

8. Contraindications in Veterinary Practice

  • Glaucoma (all types) - blocks pupillary constriction and elevates intraocular pressure
  • Obstructive GI disease (paralytic ileus, pyloric stenosis) - further impairs motility
  • Obstructive uropathy - worsens urinary retention
  • Myasthenia gravis - anticholinergic drugs worsen neuromuscular junction dysfunction
  • Cardiac arrhythmias / tachycardia - even mild tachycardia is undesirable
  • Megacolon in cats - smooth muscle relaxation worsens fecal retention
  • Pregnancy - antispasmodic medications are generally avoided in pregnant animals as safety is unestablished (Yamada's Textbook of Gastroenterology, 7e)

9. Drug Interactions

  • Other anticholinergics (atropine, glycopyrrolate): additive antimuscarinic toxicity
  • Antacids: may reduce oral absorption of dicyclomine
  • Antiglaucoma agents (pilocarpine, timolol): dicyclomine antagonizes their miotic effects
  • Phenothiazines, antihistamines, tricyclic antidepressants: enhanced anticholinergic effects
  • GI prokinetics (metoclopramide, cisapride): pharmacological antagonism - concurrent use is counterproductive

10. Available Formulations and Doses

FormulationDetails
Oral tablets10 mg, 20 mg
Oral solution10 mg/5 mL
Injection (IM only)10 mg/mL
Note: IV administration is contraindicated - causes serious adverse reactions including cardiovascular collapse in animals.
Veterinary dosing is generally extrapolated from human guidelines (0.15-0.3 mg/kg orally 2-3 times daily in dogs) with dose adjustments based on species and body weight. Always consult current formularies for species-specific dosing.

11. Summary

Dicyclomine is a synthetic antispasmodic agent with a unique dual mechanism - anticholinergic (antimuscarinic, ~1/8th atropine potency) plus direct musculotropic smooth muscle relaxation. In veterinary science, its primary value is in treating GI smooth muscle spasms in small animals, with a favorable safety profile compared to atropine due to minimal effects on heart rate, salivation, and vision. Its ability to antagonize both cholinergic and non-cholinergic (bradykinin, histamine) spasm gives it broader utility than purely antimuscarinic drugs.
Sources: Barash's Clinical Anesthesia, 9e (Classification); Yamada's Textbook of Gastroenterology, 7e (Antispasmodics); Lippincott Illustrated Reviews: Pharmacology (IBS use); DailyMed prescribing information (mechanism); RIVA-Dicyclomine monograph (animal pharmacology data).
This is a shared conversation. Sign in to Orris to start your own chat.